HOME >> BIOLOGY >> NEWS
First time in the U.S.: Saint Louis University tests third-generation vaccine against smallpox

ST. LOUIS - Not everybody can safely be vaccinated against smallpox using the current FDA-approved vaccine. Scientists hope another study vaccine, now undergoing its first testing in the United States at Saint Louis University, will give a choice to people who can't be given the current vaccine, known as Dryvax.

"There are limits to the current vaccine," said Sharon Frey, M.D., from Saint Louis University's Center for Vaccine Development. "You can't give Dryvax to people with certain skin conditions, such as eczema, or to people who are immunosuppressed. So, for example, if you are HIV-positive or undergoing chemotherapy for cancer, you shouldn't receive the currently licensed vaccine."

Dr. Frey said this study vaccine, known as MVA-BN and provided through Bavarian Nordic, is different than other vaccines that are now available. Like the current vaccines, the study vaccine is a live-virus vaccine made from vaccinia virus, but this study vaccine contains a much more "attenuated," or weakened, form of the virus.

"The thinking is that the study vaccine is much more attenuated, therefore the side effects should be less. So the hope is you may be able to give it to someone who is immunosuppressed. These are some of the questions we'll be studying as we start testing this investigational drug. If our studies prove successful, we hope this vaccine can be given to people for whom Dryvax is contraindicated."

MVA-BN also is administered in a different way. Dryvax is administered using a method called scarification, in which the skin is poked with a bifurcated needle just enough to puncture the skin. The study vaccine being tested will be administered intramuscularly, as a flu shot is given, or subcutaneously between the skin and muscle, as an insulin shot is given.

The study will enroll 90 adult volunteers into six different groups. MVA-BN will be given in three different dose strengths alone or in combination with Dryvax. The study i
'"/>

Contact: Joe Muehlenkamp
muehlenk@slu.edu
314-977-8015
Saint Louis University
10-May-2004


Page: 1 2

Related biology news :

1. First glimpse of DNA binding to viral enzyme
2. First clinical study of new pediatric croup vaccine shows safety, tolerability in adults
3. 2nd media alert First Scientific Conference on Childhood Leukaemia
4. First International Scientific Conference on Childhood Leukaemia
5. First ever standards linking climate change, biodiversity and poverty seek global peer review
6. First genetic comparison of purebred domestic dogs produces surprises
7. First target for childhood malaria vaccine
8. First study of resveratrol dietary supplement finds effect on breast and prostate cancers unlikely
9. First flavors form a lasting impression
10. STN International launches Derwent World Patents Index First View
11. First DFG research conference in the USA

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:1/4/2019)... ... January 03, 2019 , ... Stay on top of current hot topics ... industries. Access to all webinars is free, so be sure to register today to ... http://www.xtalks.com to check out our upcoming webinars, or click below to learn ...
(Date:12/20/2018)... ... December 20, 2018 , ... Human ... the completion of a new usability/observation room. This addition will help meet the ... devices and drug delivery devices/combination products are safe and easy to use when ...
(Date:12/18/2018)... ... December 18, 2018 , ... ... cancers and other serious diseases, today announced the publication of an early feasibility ... treatment of rGBM. , The publication of the study, An Early Feasibility ...
Breaking Biology News(10 mins):
(Date:12/13/2018)... ... December 11, 2018 , ... Researchers at Worcester ... to quickly detect Clostridium difficile (C. diff), a dangerous and sometimes fatal gastrointestinal ... that can be used onsite in doctor’s offices and nursing homes, providing results ...
(Date:12/13/2018)... ... December 13, 2018 , ... ... includes food (human) ingredient. This has been part of their strategic plan and ... Plan and certification creates custom fermentation opportunities for MDG within the $44 Billion ...
(Date:12/5/2018)... ... December 05, 2018 , ... The incredible life story of former ... the European Parliament by Carlos Moedas, the European Commissioner for Research and Innovation. ... in Our Daily Lives, Commissioner Moedas spoke at length of Yousef’s life and journey, ...
(Date:11/29/2018)... Utah (PRWEB) , ... November 29, 2018 , ... RAGS, ... was led by Kickstart Seed Fund, with participation from existing investor and board member ... and Davis Smith of Cotopaxi. The additional funding will enable the company to accelerate ...
Breaking Biology Technology:
Cached News: